Thirty-eight patients with nonseminomatous testicular cancer were treated with cis-platinum, bleomycin, and vinblastine in combination without a prolonged maintenance phase. Twentysix patients with Stage Ill disease were treated. Seventy-six percent of those patients treated achieved complete remission. At a median survival time of 30 months, no patient who achieved a complete remission has relapsed. Twelve Stage I1 patients given adjuvant therapy remain free of disease at a median time of 23 months. Markedly elevated serum lactate dehydrogenase levels and massive disease were common findings in the patients who did not achieve complete remission. One drug death occurred secondary to sepsis. Symptoms of depression and anxiety were significant dose-limiting factors in this group of patients. Cancer 48:lllO-1115, 1981. OLLOWING THE REPORT by Li of the success of No. 5 NONSEMINOMATOUS TESTICULAR CANCER Taylor et al. 1111
TABLE 1. Treatment Regimens VAB 111 Walter Reed Regimen Induction Day I CTX 600 mg/mz IV VLB 4 mg/mZ IV Actino-D 1 mg/mz IV Bleo 20 mg/m2/day by continuous IV Cis-platinum 120 mg/m* IV VLB 4 mg/mz IV ADR 30 mg/mz IV Chlor 4 mg/mz PO qd 1 -14 VLB 4 mg/mz IV Actino-D 1 mg/mz IV Chlor 4 mg/mz PO qd 1-14 VLB 4 mg/mz IV Cis-platinum 50 mg/mz IV Chlor 4 mg/mz PO qd 1 -14